جستجوی مقالات مرتبط با کلیدواژه "رادیوسینووکتومی" در نشریات گروه "فیزیک"

The Holmium-166 radionuclide is one of the most effective radionuclides used to treat bone marrow cancer and rheumatoid arthritis. Among the recommended radionuclides used in radiation synovectomy, 166Ho has got much attention due to suitable decay properties such as short half-life, its high beta energy, gamma-ray emission with suitable energy for nuclear imaging, and the possibility of large-scale production in medium flux reactor. One method to deliver 166Ho to the target tissue is via the 166Dy/166Ho-Chitosan in vivo generator. Compared with other similar radiopharmaceuticals, using the in vivo generator to deliver 166Ho, causes minimal non-target tissue exposure and increased absorbed dose in the target tissue. In this work, the absorbed dose of 166Dy/166Ho-Chitosan radio-complex for radio-synovectomy purposes was calculated by GEANT4 and MCNPX. The obtained results were compared with each other. In addition, the dosimetry results of the mentioned radio-complex have been compared with the common radio complexes used for radio-synovectomy.

In this study, 188-Re sulphide colloid was synthesized as a radiosynovectomy agent by reduction of sodium thiosulfate in the presence of perrhenate. The influences of the acidity, molar ratio and ultrasonic time on the colloid properties were investigated from 0.1 to 5 mol L-1; 5 to 70; and 10 to 60 min, respectively. The criteria for optimization of the influencing factors were the particle size and radiolabeling yield. Based on these factors the selected conditions were 1M HCl, thiosulfate to perrhenate molar ratio of 35 and 45 min for the ultrasonic time. The sizes of the particles were in the range of 1 to 5mm for more than 95% of the particles. The radionuclidic and radiochemical purity were found to be more than 99%. In addition, the synthesized colloid was stable for 5 days.

Radiosynovectomy is a local intra-articular injection of radionuclides in colloidal form for treatment of articular inflammatory in rheumatoid arthritis, hemophilia or orthopedic troubles. β-emitting radionuclides can be used for various joints based on radiation energy. 90Y is a pure β-emitter with a half-life of 64.1 hours that is used for treatment of the knee joint. β-radiation of this radionuclide possesses maximum energy of 2.281 MeV (99.98%), mean pathway of 3.6 mm in the soft tissue and maximum 11 mm. In this project, hydroxyapatite (HAp) is applied as a colloid maker agent that interacts with 90Y3+ ions via ion-dipole bonds and produces 90Y-HAp. The colloidal pharmaceutical is produced by adding an acidic solution of 90YCl3 to an HAp suspension in saline. Effective parameters within which the colloid is applied, such as the volume of diluent, HAp particle size and sonication effect were evaluated and tested. First, these determinative parameters were optimized in the simulated conditions and then examined in the active phase. Finally, the best procedure was determined for the production of the radiopharmaceutical. Radionuclide purity of the radiopharmaceutical according to the primary 90YCl3 solution was over 99.9%. Labeling yield and radiochemical purity were obtained over 99% using TLC method in saline solvent up to three days after production of radiopharmaceutical. Radiochemical purity of 90Y-HAp colloid was also evaluated in human serum albumin solution for three days at room temperature. The amount of released activity was between 0.3 to 2%.